UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Cell, 2017-11, Vol.171 (4), p.934-949.e16

2017

Volltextzugriff (PDF)

Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer

Current oncology (Toronto), 2022-12, Vol.30 (1), p.75-84

2022

Volltextzugriff (PDF)

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma

Oncotarget, 2019-06, Vol.10 (40), p.4018-4025

2019

Volltextzugriff (PDF)

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Annals of oncology, 2021-05, Vol.32 (5), p.661-672

2021

Volltextzugriff (PDF)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

Lung cancer (Auckland), 2020-01, Vol.11, p.59-71

2020

Volltextzugriff (PDF)

DNA mismatch repair in cancer

Pharmacology & therapeutics (Oxford), 2018-09, Vol.189, p.45-62

2018

Volltextzugriff (PDF)

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades

Frontiers in immunology, 2019-05, Vol.10, p.1113-1113

2019

Volltextzugriff (PDF)

Incidence of cancer after asthma development: 2 independent population-based cohort studies

Journal of allergy and clinical immunology, 2021-01, Vol.147 (1), p.135-143

2021

Volltextzugriff (PDF)

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Cancer cell, 2018-05, Vol.33 (5), p.853-861.e4

2018

Volltextzugriff (PDF)

Cancer type-dependent correlations between TP53 mutations and antitumor immunity

DNA repair, 2020-04, Vol.88, p.102785-102785, Article 102785

2020

Volltextzugriff (PDF)

Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report

Journal of thoracic oncology, 2018-08, Vol.13 (8), p.1217-1221

2018

Volltextzugriff (PDF)

Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients

Frontiers in oncology, 2022-09, Vol.12, p.988680

2022

Volltextzugriff (PDF)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy

Frontiers in oncology, 2021-04, Vol.11, p.672677-672677

2021

Volltextzugriff (PDF)

Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer

Frontiers in immunology, 2022-08, Vol.13, p.922780-922780

2022

Volltextzugriff (PDF)

The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study

Oral oncology, 2020-11, Vol.110, p.104943-104943, Article 104943

2020

Volltextzugriff (PDF)

B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer

Cell, 2019-11, Vol.179 (5), p.1191-1206.e21

2019

Volltextzugriff (PDF)

DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC

Journal of thoracic oncology, 2019-09, Vol.14 (9), p.1640-1650

2019

Volltextzugriff (PDF)

The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer

Cancer science, 2019-08, Vol.110 (8), p.2348-2356

2019

Volltextzugriff (PDF)

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma

Cancer Immunology, Immunotherapy, 2021-06, Vol.70 (6), p.1705-1719

2021

Volltextzugriff (PDF)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis

Frontiers in oncology, 2019-11, Vol.9, p.1161-1161

2019

Volltextzugriff (PDF)

Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors

Journal of thoracic oncology, 2021-07, Vol.16 (7), p.1086-1098

2021

Volltextzugriff (PDF)

High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients

Oncoimmunology, 2019-09, Vol.8 (9), p.e1629258-e1629258

2019

Volltextzugriff (PDF)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

Biomarker research, 2020-08, Vol.8 (1), p.34-34, Article 34

2020

Volltextzugriff (PDF)

Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions

Cancers, 2021-06, Vol.13 (13), p.3119

2021

Volltextzugriff (PDF)

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

Annals of oncology, 2020-07, Vol.31 (7), p.902-911

2020

Volltextzugriff (PDF)

1 – 25 von 2.123

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.919)
Mit Volltextzugriff
(1.955)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.975)
Life Sciences & Biomedicine
(1.839)
Mutation
(1.521)
Humans
(1.455)
Oncology
(1.081)
Female
(850)
Tumors
(822)
Tumor Burden
(684)
Male
(639)
Tumor Mutation Burden
(580)
Animals
(564)
Immunotherapy
(526)
Middle Aged
(524)
Prognosis
(485)
Cancer
(445)
Aged
(443)
Adult
(394)
Patients
(383)
Cell Line, Tumor
(380)
Mice
(365)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(1.532)
Free E-Journal (出版社公開部分のみ）
(1.508)
IngentaConnect
(1.103)
IngentaConnect Journals
(684)
Journals@Ovid Full Text
(600)
springer (창간호~2014)
(342)
Elsevier ScienceDirect Journals Complete
(309)
Publisher website
(250)
Wiley-Blackwell Journals
(225)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(204)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(128)
Nexis Uni
(125)
Nature_系列刊
(117)
Wiley Online Library Full Collection 2018
(103)
Taylor & Francis Journals
(64)
Oxford Journals
(41)
Taylor & Francis
(40)
BMJ Publishing
(30)
Oxford Journals 2020 Medicine
(29)
SAGE Journals Online
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

DNA mismatch repair in cancer

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades

Incidence of cancer after asthma development: 2 independent population-based cohort studies

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Cancer type-dependent correlations between TP53 mutations and antitumor immunity

Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report

Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy

Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer

The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study

B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer

DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC

The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis

Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors

High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

Suchergebnisse filtern